The increased number of vaginal yeast infections in the pastfew years has been a disturbing trend, and the scientific community has been searchingfor its etiology. Several theories have been putforth to explain the apparent increase. First, the recent widespread availability of low-dosage, azolebased, over-the-counter antifungal medications for vaginal yeast infections encourages women to self-diagnose and treat, and women may be misdiagnosing themselves. Their vaginitis may be caused by bacteria, parasites or may be a symptom of another underlying health condition. As a result, they may be unnecessarily and chronically expose themselves to antifungal medications and encourage fungal resistance. Second, medical technology has increased the life span of seriously immune compromised individuals, yet these individuals arefrequently plagued by opportunisticfungal infections. Long-term and intense azole-based antifungal treatment has been linked to an increase in resistant Candida and non-Candida species. Thus, thefuture of limiting antifungal resistance lies in identifying the factors promoting resistance and implementing policies to prevent it.
DEFINITION OF THE PROBLEM
Vaginal yeast infections are an unfortunate but common problem among women. It is estimated that 13 million cases are reported annually in the United States [1] . Three out of four women will experience at least one yeast infection during their reproductive years, and about half will have recurrent infections [2] . In recent years, the number of vaginal yeast infections has been dramatically increasing. In fact, not only has there been an increase in the number of vaginal yeast infections, but the number of fungal infections, in general, is on the rise. Coinciding with the increase in fungal infections is the increased use of new and old antifungal therapies. Antifungal medications have appeared on drugstore shelves, available without a prescription. Among the most visible and highly advertised antifungal medications are cures for vaginal yeast infections. It is believed that the widespread availability of these antifungals, which formerly required a prescription, has contributed to an environment conducive to breeding antifungal resistance.
Women are now more likely to selfmedicate when symptoms of itching, burning, irritation, and vaginal discharge arise. Single [8] .
Azole therapy is certainly more attractive than amp B in terms of its sideeffects, but there is a serious concern about promoting resistance through its continued use. In C. albicans, fluconazole resistance is well documented and appears to occur inherently in approximately 2 percent to 5 percent of isolates. In vivo resistance has been observed during long-term or repeated courses of azole antifungal drugs [9] . Until Several studies have assessed the changing epidemiology of candidemia. The subject populations have generally included groups with underlying immunological deficits such as AIDS, cancer, or diabetes. These groups are especially prone to fungal infections, and the morbidity and mortality by fungal infections is significantly higher than in the general population. In a multi-center, randomized, double-blind, placebo-controlled trial, the efficacy of fluconazole prophylaxis on the vaginal flora of HIV-positive women was examined. The study found that women who had taken fluconazole prophylaxis had a reduction in C. albicans colonization but an increase in the odds of being colonized with a non-albicans species, primarily C. glabrata. It illustrated the shift to non-albicans species that tend to show resistance to azole-based drugs [14] . A study on bone marrow transplant patients who received fluconazole prophylaxis indicated a correlation between antifungal therapy and in increased incidence of C. krusei. Patients who received antifungals had a seven-fold greater frequency of C. krusei infection, and the C. krusei were determined to be resistant to fluconazole in vitro [15] .
Patterns of resistance in immunecompromised groups have been extensively examined in the fungal literature. However, few studies have examined the prevalence of azole resistance in the general public or among a healthy population. Future studies might address the development of resistance in well populations as more people are employing antifungal prophylaxis without confirmed diagnosis of fungal infection.
